Curated News
By: NewsRamp Editorial Staff
September 23, 2025
Izotropic Unveils Personalized Radiation Dosing for Breast CT Imaging
TLDR
- Izotropic's radiation dose personalization feature positions its IzoView system as the first breast CT with customized dosing, offering a competitive edge in the $8.69 billion global breast imaging market.
- The system uses a radiation-free optical pre-scan and proprietary software to calculate personalized dosing based on each patient's breast size, streamlining exam setup and improving comfort.
- This innovation makes breast cancer imaging safer and more comfortable for patients while advancing early detection capabilities to improve healthcare outcomes worldwide.
- Izotropic developed the first breast CT system with real-time personalized dosing using models from UC Davis Medical Center, now advancing through FDA approval for U.S. and European markets.
Impact - Why it Matters
This development represents a significant advancement in breast cancer screening technology that directly impacts patient safety and comfort. Personalized radiation dosing addresses growing concerns about cumulative radiation exposure from medical imaging, particularly important for women who require regular breast cancer screenings. By tailoring radiation levels to individual patient anatomy, this technology could reduce unnecessary radiation exposure while maintaining diagnostic accuracy. In a field where early detection is crucial for survival rates, innovations that make screening safer and more comfortable can encourage higher compliance with recommended screening protocols. For healthcare providers, this technology offers the potential for more efficient workflow and reduced liability concerns related to radiation exposure. As breast cancer remains one of the most common cancers affecting women worldwide, advancements in screening technology that improve both safety and accuracy have far-reaching implications for public health outcomes and healthcare costs.
Summary
Izotropic Corporation (CSE: IZO, OTCQB: IZOZF, FSE: 1R3), a medical device company specializing in advanced breast cancer imaging technologies, has announced a significant technological advancement for its IzoView Breast CT Imaging System. The company is integrating a patent-pending radiation dose personalization feature that represents a breakthrough in patient-specific care. This innovation utilizes a radiation-free optical pre-scan combined with proprietary software to calculate customized radiation dosing based on each patient's unique breast size and composition. The development, which leverages models from UC Davis Medical Center, positions IzoView as the first breast CT system capable of offering real-time personalized dosing, potentially setting a new standard in the breast imaging market projected to reach $8.69 billion by 2030.
The integration of this personalized dosing technology addresses critical challenges in breast cancer screening by streamlining exam setup procedures while simultaneously improving patient comfort and safety. By eliminating the one-size-fits-all approach to radiation exposure, Izotropic is advancing its IzoView system through the FDA Pre-Market Approval process with preparations underway for pivotal U.S. clinical trials. The company's strategic focus on both U.S. and European markets underscores the global significance of this innovation. For investors and stakeholders, more information about Izotropic Corporation can be found on its website at izocorp.com and through its profile on SEDAR at sedarplus.ca, while the latest updates are available in the company's newsroom.
The announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN that provides advanced wire-grade press release syndication services. InvestorWire offers comprehensive distribution solutions including access to extensive wire networks, article syndication to over 5,000 outlets, enhanced press release features, and social media distribution through IBN's millions of followers. This robust distribution network ensures that groundbreaking medical innovations like Izotropic's personalized dosing technology reach the appropriate investment communities, healthcare professionals, and regulatory stakeholders necessary for successful commercialization in the competitive medical device landscape.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Izotropic Unveils Personalized Radiation Dosing for Breast CT Imaging
